SCHEMBL6764182

SCHEMBL6764182

O=C(O)CNC(=O)CN(C1CC1)S(=O)(=O)c1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.44
USP2 O75604 3/20 0.43
TSHR P16473 2/20 0.43
TP53 P04637 1/20 0.43
ALOX15 P16050 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
USP5 P45974 1/20 0.41
FAAH O00519 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764162 0.91 RORC (0.41) HTTUSP2TSHRTP53ALOX15
SCHEMBL6764088 0.87 USP2 (0.42) USP2TSHRTP53ALOX15KMT2A
SCHEMBL6764156 0.80 ALDH1A1 (0.51) HTTKMT2ALMNAALDH1A1
SCHEMBL5125364 0.76 HTT (0.52) HTTKMT2AMEN1FAAHALDH1A1
SCHEMBL5118595 0.75 HTT (0.45) HTTKMT2AMAPTFAAHALDH1A1
SCHEMBL6764048 0.73 BDKRB1 (0.65)
SCHEMBL6884912 0.71 MCOLN3 (0.49) HTTUSP2TSHRKMT2AMEN1
SCHEMBL6764149 0.69 ALDH1A1 (0.43) HTTKMT2AUSP5ALDH1A1
SCHEMBL6763996 0.69 POLB (0.45) HTTKMT2AMAPTALDH1A1
SCHEMBL6764188 0.68 POLB (0.39) HTTKMT2AMEN1USP5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use LABORATORIES FOURNIER S.A. (FR) 2004-04-01 US disclosed
EP-1351928-A2 NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER S.A. (FR) 2003-10-15 EP disclosed
WO-2002053516-A2 N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER SA (FR) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use GLS, GLS2, GLRB HTT 614/4885USP2 2448/4885TSHR 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.